Nasdaq GlobeNewswire

Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs

Del

- IND submitted to U.S. FDA for MCLA-117 in AML -

- First CTA approval for MCLA-158 received in European country - 

UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-117 for the potential treatment of acute myeloid leukemia (AML) and the approval of a Clinical Trial Application (CTA) in Belgium for MCLA-158 for the potential treatment of metastatic colorectal cancer.

"The filing of an IND for MCLA-117 and the first CTA approval for MCLA-158 represent key steps forward for both programs as we continue to progress our robust pipeline of proprietary bispecific antibodies in the clinic with the goal of addressing significant unmet medical needs," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. "We look forward to the advancement of both Biclonics® in 2018, including the initiation a Phase 1 first-in-human trial of MCLA-158 in Belgium planned for this quarter."

Merus today announced that it has submitted an IND application to the U.S. FDA for MCLA-117, the Company's T-Cell Engager Biclonics®, designed to specifically bind to CD3, a cell-surface molecule present on T cells, and CLEC12A, a cell-surface molecule present on AML cells and stem cells. MCLA-117 is currently being studied in an ongoing Phase 1, first-in-human, dose escalation clinical trial in Europe in AML patients with relapse or refractory disease.  Upon acceptance of the IND by the U.S. FDA, Merus plans to open sites for this trial in the United States.

The Company also announced approval of a CTA in Belgium, one of the several European countries where Merus has filed a CTA and where it plans to first initiate a Phase 1, first-in-human clinical trial of MCLA-158. MCLA-158 is an ADCC-enhanced Biclonics® designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptors (EGFR).  The trial, which will focus initially in patients with metastatic colorectal cancer, is anticipated to start during the first quarter of 2018. Merus plans to file an IND for MCLA-158 with the U.S. FDA in the first quarter of 2018.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is expected to soon be evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target and is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus' website, www.merus.nl.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the progress of Merus' robust pipeline of proprietary bispecific antibodies in the clinic with the goal of addressing significant unmet medical needs, the advancement of MCLA-117 and MCLA-158 through 2018, including the timing of initiating clinical trials, plans to open sites in the U.S. for the ongoing Phase 1 clinical trial of MCLA-117, the initial focus on metastatic colorectal cancer for the Phase 1 clinical trial for MCLA-158 and filing an IND in the U.S. for MCLA-158 in the first quarter of 2018, the timing of the Phase 2 combination trial of MCLA-128 in metastatic breast cancer and the potential of MCLA-158 to treat colorectal cancer and other solid tumors.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in existing and potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts:

Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly@argotpartners.com

Media:
David Rosen
+1 212-600-1902
david.rosen@argotpartners.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CP Kelco Appoints Jennifer Aspen Mason as Sr. Vice President, Global Innovation22.2.2018 20:00Pressemelding

ATLANTA, Feb. 22, 2018 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Jennifer Aspen Mason has joined its Executive Leadership Team as Senior Vice President, Global Innovation, reporting directly to CP Kelco President Didier Viala. A global executive with more than 20 years of industry experience, Mason has an extensive background leading science organizations with Fortune 100 companies. Most recently, she spent more than five years with Mars, Incorporated, where she served as Technology and Science Strategy Officer for all Mars segments. In her new role, Mason is responsible for leading CP Kelco's global research and development (R&D) function, including strategic innovation imperatives to drive the company's long-term growth, as well as oversight of technical teams focused on new product innovation, process R&D and research. "We are truly delighted to welcome Jennifer to our team, and will surely benefit from her glob

Leading the industry: Excel Dryer is the first hand dryer manufacturer to publish third-party, verified Environmental Product Declarations (EPDs)22.2.2018 16:00Pressemelding

High-speed, energy-efficient XLERATOR®, XLERATOReco® and ThinAir® Hand Dryers evaluated and proven to be sustainable EAST LONGMEADOW, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Excel Dryer, Inc., today announced that three of their hand dryers, the original, patented, high-speed, energy-efficient XLERATOR® Hand Dryer, the XLERATOReco® Hand Dryer and the ThinAir® Hand Dryer, were evaluated, and their environmental claims, substantiated with the publication of the hand dryer industry's first Environmental Product Declarations (EPDs) by UL Environment, a business division of Underwriters' Laboratories. An Environmental Product Declaration is a standardized way of quantifying the environmental impact of a product by studying the raw materials and energy consumption during its production, use and disposal. For buyers and specifiers, the EPDs are a disclosure tool that helps purchasers better understand a product's sustainable qualities and environmental repercussions so they can make more inf

Intrinsyc Technologies (TSX: ITC and OTC: ISYRF) debuts system on module and development kit powered by NXP i.MX 8M processor22.2.2018 15:00Pressemelding

Powerful Embedded Computing Solutions Optimized for Multimedia Applications VANCOUVER, British Columbia, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Intrinsyc Technologies Corporation (TSX:ITC) (OTC:ISYRF) ("Intrinsyc" or the "Company"), a leading provider of solutions for the development and production of embedded and Internet of Things ("IoT") products, today announced the availability of the Open-X(TM) 8M System on Module ("SOM") and Development Kit. Intrinsyc's Open-X(TM) 8M SOM incorporates the new 64-bit NXP i.MX 8M processor and is ideal for powering IoT devices ranging from consumer smart home appliances to industrial building automation products. Its ultra-compact (55mm x 35mm) size enables its use in a wide range of form factors. The feature-rich SOM, with its advanced video and audio features, is ideal for streaming video/audio devices, voice control applications, and human-machine interface solutions. It offers high quality video playback with full 4K UHD and HDR along with the highe

Danal Inc. Creates Largest and Best Global Mobile Identity Solution22.2.2018 14:00Pressemelding

On track to cover 3 Billion+ Consumers SAN JOSE, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Danal, Inc., a global leader in mobile identity and authentication services, today announced that customer demand is driving its expansion into Asia and LATAM. The company is expanding to eight countries in Asia and LATAM this year in addition to its continued expansion in Europe and UK - creating the largest and most comprehensive Mobile Network Operator (MNO) based identity solution in the market. It is on track to cover over 3 Billion consumers worldwide and support numerous Fortune 500 Enterprises in their endeavor to fight fraud, account takeovers, assuring reliable consumer authentication with best in class experiences, and help conform to regulatory compliance including GDPR, TCPA, KYC and AML. Danal is experiencing strong demand by global brands for the US, EU, and Asian markets - especially in the financial sector like banks, insurances, money remitters, payment processors and innovative

Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA22.2.2018 13:00Pressemelding

BRIDGEWATER, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, today announced it has signed an exclusive distribution agreement with Movi SpA ("Movi") for the commercialization of V-Go Wearable Insulin Delivery device in Italy. Under the terms of the agreement, Valeritas has granted Movi the rights to promote, market, and sell the Company's flagship product V-Go Wearable Insulin Delivery device to diabetes clinics and patients in Italy. "We are thrilled to have Movi as our partner, and our distribution agreement is a significant first step to expand market access for V-Go Wearable Insulin Delivery device outside of the United States," said John Timberlake, CEO and President of Valeritas. "Movi is a truste

SoftServe Appoints Alex Chubay as Chief Technology Officer22.2.2018 13:00Pressemelding

Chubay to Champion the Next Phase of Innovation and Growth at World-Class Digital Consultancy AUSTIN, Texas, Feb. 22, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading global digital authority and consulting company, today announces its appointment of Alex Chubay as Chief Technology Officer, effective immediately. Chubay will lead global IT functions and play a key role in shaping the company's technology capabilities and roadmap. He will be responsible for SoftServe's Centers of Excellence, comprising Experience Design, Solutions, Intelligent Enterprise, Critical Services, Digital Platforms; as well as research and development within the company. He will report to SoftServe's CEO, Chris Baker. "SoftServe has operated at the cutting edge of technology for a quarter century, and to continue that momentum - and most importantly to ensure our customers, partners, and associates are served well in the future - we are delighted to announce Alex Chubay's appointment as CTO," said Baker. "This ne

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom